Research · Sep 3, 2026
[OSIS] OSI Systems Thesis 2026: A Security-Healthcare-Optoelectronics Trifecta Rides TSA-and-Border Modernization
OSI Systems Inc (NASDAQ: OSIS), headquartered in Hawthorne, California (Los Angeles area), is a global supplier of specialty electronic-systems producing security-screening + healthcare-monitoring + optoelectronic components for aviation-security + cargo + customs-and-border + hospital-and-clinical + aerospace + defense + industrial customers globally. Founded in 1987 by Deepak Chopra in Hawthorne, California with selectively-distinctive multi-decade founder-led-and-controlled history, IPO'd 1997 on NASDAQ, and has operated continuously for ~38 years. Through multi-decade strategic-evolution OSI built three-division diversified-specialty-electronics-business (Security + Healthcare + Optoelectronics), executed selective M&A including Spacelabs Healthcare 2004 (acquired from Datex-Ohmeda for ~$70M as multi-decade-strategic-Healthcare-platform-acquisition), AB Precision UK 2010, Aviation Security Solutions UK 2011, and other bolt-ons, built dominant US-aviation-security + cargo-screening franchise via Rapiscan Systems, and multi-decade Deepak Chopra founder-and-family-controlled stewardship. Under President & CEO Deepak Chopra (CEO since founding 1987, co-founder + longtime CEO with family-control + selectively-distinctive multi-decade founder-led-and-controlled diversified-specialty-electronics company), FY2025 closes with selected various aggregate revenue ~$1.65-1.80B (~10-15% YoY growth), adjusted EBITDA ~$0.27-0.32B (~16-18% margins), adjusted EPS ~$8.85-10.20, and ~17M shares outstanding. The first deep-dive — Security division + Rapiscan Systems X-ray + trace-explosive-detection franchise — covers the dominant ~55-60% of revenue + multi-decade-aviation-security-and-cargo-screening engine. Security (~$0.95-1.05B) provides X-ray + trace-explosive-detection equipment for aviation-security + cargo + customs-and-border + checkpoint + civil-aviation + military-checkpoints via Rapiscan Systems sub-brands (Rapiscan dominant US-aviation-security carry-on + hold-baggage scanners + CT-X-ray + AI-augmented Rapiscan 920-CT/930-CT), Eagle drive-through cargo-and-truck-screening (selectively-dominant US-Mexico-border + US-Canada-border + international ports), ITEMISER trace-explosive-detection, body-scanners + hand-held + other specialty-detection. Customer base: TSA (Transportation Security Administration, dominant US-aviation-security with ~430+ federalized-US-airports requiring ongoing-modernization + CT-X-ray rollout + AI-augmented threat-detection), Customs and Border Protection (CBP, cargo + truck-and-vehicle inspection via Eagle), DHS, DoD, international aviation-and-customs (UK + EU + Middle East + Asia + Africa + Latin America). Backlog ~$1.5-2.5B providing ~12-24-month revenue-visibility (multi-year IDIQ TSA-and-CBP contracts). Competitive position: selectively-dominant US-aviation-security + cargo-screening reflecting multi-decade TSA-and-CBP-customer-relationship + program-engineering-integration + certified-product-portfolio depth (TSA-CertScreen + others) + Rapiscan brand-equity + global-installed-base + service-and-aftermarket footprint. FY2026 catalyst is TSA-airport-modernization (CT-X-ray rollout + AI-augmented threat-detection upgrade-cycle), CBP-spending (Eagle cargo + vehicle + Mexico-and-Canada-border), international aviation-security cycle, and selective new-program-wins. Competes with Smiths Detection (subsidiary of Smiths Group SMIN-LN, the most-direct global comp + selectively-largest aviation-security + cargo-screening market share), Leidos Holdings (LDOS, broader government-services + L3Harris Security Detection assets), Analogic (private since 2018 Altaris), Nuctech (private Chinese state-owned), Vidisco (private Israeli), Astrophysics (private); in trace-explosive-detection Smiths Detection IONSCAN, FLIR Systems (Teledyne FLIR), Bruker (BRKR); in body-scanners L3Harris (LHX), Smiths Detection. The second deep-dive — Healthcare + Optoelectronics + multi-decade compounder thesis — covers two additional segments + multi-decade founder-led-and-diversified strategy. Healthcare (~$0.45-0.55B, ~25-30%) provides Spacelabs patient-monitoring (selectively-distinctive hospital-patient-monitoring including cardiac + vital-signs + neonatal + telemetry, acquired 2004 from Datex-Ohmeda for ~$70M as multi-decade-strategic-platform), Cardiology (ECG + cardiac-rhythm + Holter + stress-test), Anesthesia delivery + ventilation, Diagnostic-equipment + telemetry, Healthcare-IT + connected-care platforms. Selectively-niche-and-stable but pressured by larger comps Philips Healthcare, GE HealthCare (GEHC), Mindray (300760-CN), Medtronic (MDT), Abbott (ABT). Optoelectronics and Manufacturing (~$0.25-0.30B, ~15-20%) provides custom optoelectronic components + EMS for medical + aerospace + defense + industrial customers leveraging OSI's vertical-integrated optoelectronics-and-EMS expertise + India-based-manufacturing-cost-advantage. Multi-decade compounder thesis combines Security dominant-niche-position + TSA-and-CBP-customer-base moat, Healthcare niche-stable-cash-flow, Optoelectronics steady-cash-flow, Deepak Chopra founder-and-family-control multi-decade-disciplined-capital-allocation (~38-year founder-CEO continuity), selective M&A, and operational-leverage. Capital position is moderately-leveraged, no-dividend, opportunistic-buyback: net debt ~$0.60-0.85B providing ~2.0-3.0x leverage, BB+/BBB- IG-adjacent (S&P split-rating), ~$0.05-0.15B cash + undrawn revolver liquidity, FCF ~$100-180M/yr deployed into selective bolt-on M&A + opportunistic-buybacks + debt-paydown, no regular dividend, ~$50-200M+/yr opportunistic buybacks, ~17M Class A common (selectively-decreasing from ~22-25M ~2010). Deepak Chopra founder-and-insider-and-family ~5-10%+. At ~$160-220 per share, equity value ~$2.7-3.7B, EV ~$3.3-4.5B, ~17-24x EPS and ~11-15x EV/EBITDA. Base case: revenue grows ~10-13% + EBITDA-margin ~16-18% + EPS $9.50-11.50 + bolt-on M&A + buybacks + ~10-22% return. Bull case: TSA-CBP accelerates + Healthcare accelerates + EBITDA-margin ~18-20% + EPS $11.50-14.00 + re-rate 22-28x + 30-50%+ return. Bear case: TSA-procurement-delays + Smiths competitive-share-loss + EPS $7.50-9.00 + de-rate 14-17x + flat-to-negative.